These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8288425)

  • 21. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 22. Recombinant human erythropoietin use in hemolytic anemia due to prosthetic heart valves: a promising treatment.
    Hirawat S; Lichtman SM; Allen SL
    Am J Hematol; 2001 Mar; 66(3):224-6. PubMed ID: 11279631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost of treating predialysis patients with recombinant human erythropoietin.
    Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
    Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin.
    Adamson JW; Eschbach JW
    Annu Rev Med; 1990; 41():349-60. PubMed ID: 2184735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
    Lundin AP
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
    Holley JL; Nolan TA; Piraino B
    Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to erythropoietin: immunohemolytic anemia induced by residual formaldehyde in dialyzers.
    Ng YY; Chow MP; Lyou JY; Hu HY; Yung CH; Fan CD; Huang TP
    Am J Kidney Dis; 1993 Feb; 21(2):213-6. PubMed ID: 8430685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of recombinant erythropoietin therapy for renal transplantation.
    Ward HJ
    Am J Nephrol; 1990; 10 Suppl 2():44-7; discussion 48-52. PubMed ID: 2260618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia.
    Finkelstein SN; Huber SL; Greenberg PE
    Ann Pharmacother; 1997 Sep; 31(9):1094-5. PubMed ID: 9296258
    [No Abstract]   [Full Text] [Related]  

  • 31. [Prevention and therapy of renal anemia].
    Schulz E; Heinecke G
    Dtsch Med Wochenschr; 1973 May; 98(20):1040-3. PubMed ID: 4575063
    [No Abstract]   [Full Text] [Related]  

  • 32. Erythropoietin therapy for premature infants: cost without benefit?
    Zipursky A
    Pediatr Res; 2000 Aug; 48(2):136. PubMed ID: 10926284
    [No Abstract]   [Full Text] [Related]  

  • 33. [Human recombinant erythropoietin: from clinical aspects to the physiopathology of anemia of renal insufficiency].
    Wauters JP
    Rev Med Suisse Romande; 1990 Nov; 110(11):951-4. PubMed ID: 2267466
    [No Abstract]   [Full Text] [Related]  

  • 34. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities.
    House AA; Pham B; Pagé DE
    Nephrol Dial Transplant; 1998 Jul; 13(7):1763-9. PubMed ID: 9681725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of polytransfused hemodialysis patients with recombinant human erythropoietin.
    Bommer J; Huber W; Tewes G; Ritz E; von Wedel S; Küppers S; Weinreich T; Bommer G
    Contrib Nephrol; 1988; 66():131-8. PubMed ID: 3391027
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
    Driver PS
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ; Petersen J
    West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.
    Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Pennington S; Vale L; Wallace S; MacLeod A
    Cochrane Database Syst Rev; 2001; (4):CD003266. PubMed ID: 11687180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietin, an update, and where to in the future?
    Sulková S
    EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
    Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
    N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.